Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CODEINE PHOSPHATE

2 general benefit · 1 not a benefit

Teva-Codeine · DIN 00593435 · 15mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Codeine · DIN 00593435 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2017-11-17 · brand TEVA-CODEINE · ATC R05DA04 CODEINE · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 15 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Teva-Codeine: Formulary list price $0.0596/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0596 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6415 · Verify on the e-Formulary ↗ (DIN 00593435)

Source record
DIN 00593435: Teva-Codeine Raw flags: sec3=Y Item: 280808010; group id 400; item number 0955; lccId None; manufacturer id TEV Source form: Tab; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $0.0596; ministry $0.0596 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00593435 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6415
Interchangeable products
Codeine · DIN 00779458 · not recorded
Shortage status: resolved shortage (ended 2026-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00593435
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Codeine · DIN 00593451 · 30mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Teva-Codeine · DIN 00593451 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2017-11-17 · brand TEVA-CODEINE · ATC R05DA04 CODEINE · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 30 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Teva-Codeine: Formulary list price $0.0966/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0966 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6416 · Verify on the e-Formulary ↗ (DIN 00593451)

Source record
DIN 00593451: Teva-Codeine Raw flags: sec3=Y Item: 280808011; group id 400; item number 0956; lccId None; manufacturer id TEV Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.0966; ministry $0.0966 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00593451 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6416
Shortage status: resolved shortage (ended 2026-04-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00593451
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Codeine · DIN 00779458 · 15mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-01 — choose a marketed DIN from the same-category list.Discontinued 2015-10-01 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2015-10-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Codeine · DIN 00779458 Manufacturer: Rougier Pharma, Division of Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2015-10-01 · brand CODEINE TAB 15MG · ATC R05DA04 CODEINE · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 15 MG · company Rougier pharma division of ratiopharm inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Codeine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9439 · Verify on the e-Formulary ↗ (DIN 00779458)

Source record
DIN 00779458: Codeine Raw flags: notABenefit=Y, sec3=Y Item: 280808010; group id 400; item number 0955; lccId None; manufacturer id ROG Source form: Tab; strength: 15mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00779458 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9439
Interchangeable products
Teva-Codeine · DIN 00593435 · $0.0596
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00779458
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2015-10-01 — choose a marketed DIN from the same-category list.

CODEINE SULFATE TRIHYDRATE & MONOHYDRATE

All strengths: Limited Use — Reason for Use code 201 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 201 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Codeine Contin · DIN 02230302 · 50mg · CR tablet

Limited Use — Reason for Use code 201 requiredMarketed · checked 2026-09-20
Write on scriptLU code 201 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02230302 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1997-03-13 · brand CODEINE CONTIN 50MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) 50 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Codeine Contin: Formulary list price $0.5137/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5137 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49057 · Verify on the e-Formulary ↗ (DIN 02230302)

Source record
DIN 02230302: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808101; group id 401; item number 0957; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.5137; ministry $0.5137 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230302 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49057
Shortage status: resolved shortage (ended 2024-01-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230302
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Codeine Contin · DIN 02163748 · 100mg · CR tablet

Limited Use — Reason for Use code 201 requiredMarketed · checked 2026-09-02
Write on scriptLU code 201 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02163748 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1995-12-31 · brand CODEINE CONTIN 100MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) 100 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Codeine Contin: Formulary list price $1.0285/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0285 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19050 · Verify on the e-Formulary ↗ (DIN 02163748)

Source record
DIN 02163748: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808107; group id 401; item number 0958; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0285; ministry $1.0285 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163748 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19050
Shortage status: resolved shortage (ended 2026-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163748
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Codeine Contin · DIN 02163780 · 150mg · CR tablet

Limited Use — Reason for Use code 201 requiredMarketed · checked 2026-09-20
Write on scriptLU code 201 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02163780 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1995-12-31 · brand CODEINE CONTIN 150MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE SULFATE TRIHYDRATE, CODEINE MONOHYDRATE) 150 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Codeine Contin: Formulary list price $1.5434/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.5434 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19051 · Verify on the e-Formulary ↗ (DIN 02163780)

Source record
DIN 02163780: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808108; group id 401; item number 0959; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.5434; ministry $1.5434 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163780 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19051
Shortage status: resolved shortage (ended 2023-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163780
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Codeine Contin · DIN 02163799 · 200mg · CR tablet

Limited Use — Reason for Use code 201 requiredMarketed · checked 2026-09-02
Write on scriptLU code 201 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02163799 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1995-12-31 · brand CODEINE CONTIN 200MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) 200 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Codeine Contin: Formulary list price $2.0571/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0571 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19049 · Verify on the e-Formulary ↗ (DIN 02163799)

Source record
DIN 02163799: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808109; group id 401; item number 0960; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0571; ministry $2.0571 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163799 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19049
Shortage status: resolved shortage (ended 2023-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163799
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg · Cap

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08 and 1 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2) INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10 Product monograph BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CELECOXIB · Limited Use, codes 316, 317 1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10 Product monograph HYDROMORPHONE HCL · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) 1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. PM: https://pdf.hres.ca/dpd_pm/00072218.PDF; date August 29, 2023; DIN 00125083; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults TEVA-CODEINE is indicated for the symptomatic treatment of mild to moderate pain of various causes and the control of exhausting, nonproductive cough which does not respond to non-opioid antitussives. TEVA-CODEINE is not indicated as an as-needed (prn) analgesic. Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics). Pediatrics (< 18 years of age) The safety and efficacy of TEVA-CODEINE has not been studied in the pediatric population. The use of TEVA-CODEINE is not recommended in patients between 12 and 18 years of age, and is contraindicated in those under 12. Contraindicated in < 12 years of age for any use: Regardless of the clinical setting, the use of codeine is contraindicated in patients below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see … https://pdf.hres.ca/dpd_pm/00053875.PDF PM date: November 5, 2019 Source product: TEVA-CODEINE; DIN 00593435; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. CODEINE CONTIN is not indicated as an as-needed (prn) analgesic. 1.1 Pediatrics Pediatrics (<18 years of age): Regardless of the clinical setting, codeine, including CODEINE CONTIN, should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see 2 Contraindications; 4 Dosage and Administration; 7.1.3 Pediatrics; 10.3 Pharmacokinetics, Special Populations and Conditions, Pediatrics) CODEINE CONTIN has not been studied in the pediatric population, therefore the use of CODEINE CONTIN is not recommended in patients over 12 and under 18 years of age (see 2 Contraindications). 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. (see 7.1.4 Geriatrics; 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). In general, dose selecti… https://pdf.hres.ca/dpd_pm/00078791.PDF PM date: 2025-03-04 Source product: CODEINE CONTIN 100MG CONTROLLED RELEASE TAB; DIN 02163748; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Codeine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026